News
Is Pfizer Stock Ready to Bounce Back?
Pharmaceutical giant Pfizer (NYSE: PFE) has been in a bit of a freefall since early 2022, with shares down by 46%. Pfizer's revenue and earnings dropped off a cliff along with its
3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More
What do income investors like better than a stock that pays a juicy dividend yield? The answer is easy: A stock with a juicy dividend yield that's likely to grow its dividend payout over time.
Such
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond
Many stocks have been enjoying major gains as the bull market has persisted, driving up shares prices of companies across various indexes. If you're investing for the long term, what's more
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
You might think that if a drugmaker has a top-selling drug, it would be a lock to be a top-performing stock and a no-brainer buy. That may be true in some cases. In others, it can be a source of
3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income
If you're a retiree looking to make the most of your nest egg, putting money into dividend stocks can be a great way to do that. You can help maximize the recurring income you earn by investing in
Looking for Safe Dividend Income? These 3 Stocks Have Rock-Solid Payouts.
If you're buying a dividend stock, you need to carefully consider not just the payout ratio but also the company's long-term prospects. Intel suspended its dividend recently, an example of a
3 Fantastic Growth Stocks to Buy in August
The recent stock market sell-off appears to have fizzled out and now could be a great time for long-term investors to put some of their cash to work.
Three Motley Fool contributors think they've
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline
If you're looking for a top healthcare company to invest in, you may want to consider looking at one that has multiple fast-growing products in its portfolio. By seeking out diversified growth
Why Pfizer Stock Slumped on Friday
In the thick of the coronavirus pandemic several years ago, any positive news from a developer of COVID-19 vaccines or drugs would have been met with a surge of buying in its stock. We're not in
Why Victoria's Secret Stock Was Soaring This Week
A fresh change in leadership, unexpectedly strong preliminary results, and a set of bullish new analyst notes were the main factors pushing Victoria's Secret (NYSE: VSCO) stock higher in recent
1 Growth Stock Down 43% to Buy Right Now
Attractive investment opportunities can sometimes arise when investors react emotionally to short-term events. Some of these events revolve around the earnings season, when a company releases
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
The diabetes and obesity care markets are under disruption. Glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, Wegovy, Mounjaro, and Zepbound have catapulted in popularity.
The thing
Why Victoria's Secret Stock Was Climbing Today
Shares of Victoria's Secret (NYSE: VSCO) were surging today after the struggling apparel company named a new CEO, Hillary Super. Investors seem to be hopeful that the move will lead to a turnaround
RAMQ Expands Provincial Coverage to Include Dexcom G7, Bringing the Next-Generation CGM System to More Québec Residents
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its latest innovation, the Dexcom G7 Continuous
Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?
According to a bullish Wall Street analyst, Abbott Laboratories (NYSE: ABT) stock could outperform for investors. Following the company's latest earnings report, Matt Miksic from Barclays maintained
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
The market is a bit jittery right now thanks to a confluence of factors, including a weaker-than-anticipated U.S. jobs report, international geopolitical issues, and foreign currency disruptions --
3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With $100 Now
Would you like to improve your passive income stream but don't have a lot of extra cash to throw around? If so, I have great news: These days, $100 is all it takes to acquire a share of three top
Is Pfizer Stock a Buy Now After Earnings?
While the COVID-19 pandemic is an increasingly distant memory for most investors, Pfizer (NYSE: PFE) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
One thing that can help with the treatment of any disease is early detection, and Alzheimer's is no exception to that. And the good news is that in the near future, detecting cases of Alzheimer's
3 Stocks Retirees Should Absolutely Love
Many retirees are investors for a good reason: They can't rely entirely on Social Security to fund their retirement. Investing wisely provides a means to retire comfortably.
Three Motley Fool
Should You Buy DexCom Stock After Its Post-Earnings Sell-Off?
When a stock falls over a cliff after earnings, it can put investors into an unnerving situation: Should you average down, or simply get out of the stock entirely? It's not always an easy question
These Stocks Just Dropped by 40% and 15% -- Should You Buy the Dip?
Earnings season can be a volatile time in the stock market. Some corporations produce financial results that are impressive enough to send their share prices soaring, while others move in the exact
Should Pfizer's Strong Quarter Calm Investor Concerns About the Stock?
Demand for COVID-19 vaccines and drugs has been fading for a while now. And that has put a big dent in Pfizer's (NYSE: PFE) sales and profit numbers. On top of that, the stock is also facing
Here's Why Eli Lilly Stock Dropped 12% Last Month
Shares of Eli Lilly (NYSE: LLY) fell 20% in July, according to data from S&P Global Market Intelligence. The pharmaceutical stock tumbled after one of the company's competitors announced promising
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q2 2024 Earnings CallAug 07, 2024, 4:30 p.m. ET
Operator
Source Fool.com